Drug Trial Radar · NCT05627375
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets
Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,400
Planned (sponsor's estimate)
Start
Aug 16, 2023
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire de Saint EtienneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health, France
- First posted
- Nov 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Venous thromboembolism (VTE) and atherosclerotic cardiovascular disease share common risk factors and frequently coexist in the same patients. Their management requires use of antithrombotic agents: anticoagulant therapy (AC) for secondary prevention of VTE recurrence, antiplatelet (AP) for secondary prevention of major adverse ischemic cardiovascular and cerebrovascular event (MACCE) in patients with atherosclerotic cardiovascular disease (coronary artery disease, atherosclerotic cerebrovascular disease, lower extremity peripheral arterial disease). Side effects of antithrombotic drugs are the 1st cause of emergency admission and hospitalization for an adverse drug reaction (mainly bleeding), and the combination of AC with AP strongly increases this risk.
Conditions
- Venous Thromboembolic Disease
Interventions
Full-dose anticoagulant therapy (AC)Drug
Anticoagulant (AC) therapy: at the investigator's discretion in accordance with international recommendations for the management of DVT/PE
Antiplatelet therapy (AP)Drug
Aspirin (at a daily dose ≤100 mg) or Clopidogrel (at a daily dose ≤75mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinically relevant bleedingTime frame: end of the full-dose treatment period, up to 12 months
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
CHU Amiens
Amiens, France · Recruiting
CHU Angers
Angers, France · Recruiting
CHU Besançon - Hôpital Jean Minjoz
Besançon, France · Recruiting
CHRU Brest - Hôpital la Cavale Blanche
Brest, France · Recruiting
Clinique du Parc - Castelnau-le -lez
Castelnau-le-Lez, France · Recruiting
CHU Clermont-Ferrand - Hôpital Gabriel Montpied
Clermont-Ferrand, France · Recruiting
CHU Dijon
Dijon, France · Recruiting
CH le Corbusier - Firminy
Firminy, France · Recruiting
CHU Grenoble - Hôpital la Tronche
Grenoble, France · Recruiting
CH Le Puy - Hôpital Emile Roux
Le Puy-en-Velay, France · Recruiting
CHU Limoges
Limoges, France · Recruiting
HCL - Hôpital Edouard Herriot
Lyon, France · Recruiting
HCL - Lyon Sud
Lyon, France · Recruiting
APHM - Hôpital la Timone
Marseille, France · Recruiting
CH du Forez - Montbrison
Montbrison, France · Recruiting
CHU Montpellier
Montpellier, France · Recruiting
CHU Nancy - Hôpitaux de Brabois
Nancy, France · Recruiting
CHU Nantes - Hôpital Hôtel-Dieu
Nantes, France · Recruiting
CHU de Nice - Hôpital Pasteur
Nice, France · Recruiting
APHP - Hôpital Bicêtre
Paris, France · Recruiting
APHP - Hôpital Européen Georges Pompidou HEGP
Paris, France · Recruiting
APHP - Hôpital Louis Mourier
Paris, France · Recruiting
CHU Rouen
Rouen, France · Recruiting
CHU Saint-Etienne
Saint-Etienne, France · Recruiting
CHU Strasbourg - Nouvel Hôpital Civil
Strasbourg, France · Recruiting
CH Toulon - Hôpital Sainte Musse
Toulon, France · Recruiting
CHU Toulouse - Hôpital de Rangueil
Toulouse, France · Recruiting
CHU Tours
Tours, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.